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Abstract
Viral hepatitis negatively affects the health of millions, with the worst health outcomes
associated with the hepatitis D virus (HDV). Fortunately, HDV is rare and requires prior
infection with the hepatitis B virus (HBV) before it can establish infection and transmit.
Here, we develop a mathematical model of HBV and HDV transmission in Sub-Saharan
Africa to investigate the effects of hepatitis B vaccination on both HBV and HDV. Our
findings illustrate a hepatitis B vaccination rate above 0.006 year−1 reduces hepatitis D by
over 90%, and a vaccination rate above 0.0221 year−1 reduces hepatitis B by over 90%,
respectively. These results suggest a modest scale-up of current hepatitis B vaccination
rates is required to achieve the 90% reduction targets set by health authorities. Thus, with
sufficient investments to scale up global hepatitis vaccination, the health burden of HBV and
HDV can dramatically be reduced, making their potential elimination feasible endeavors.
Keywords: Viral hepatitis, Compartmental models, differential equations, Hepatitis Action
Plan, Hepatitis B vaccination



1

Introduction

Hepatitis viruses are estimated to infect 2.3 billion individuals worldwide [11]. Of these individuals, the 12.4 million [15, 33] who are chronically co-infected with the hepatitis B (HBV) and hepatitis D (HDV) viruses face the
worst prognosis, as the odds of liver cancer are more likely,
and the progression towards liver-related death occurs
much more rapidly [33]. Fortunately, two key facts offer hope against these negative outcomes. First, HDV
infection is uncommon, as it requires infection with HBV
to infect and transmit [33]. Second, the annual incidence
of HBV continues to plummet in many regions due to
the successful rollout of highly efficacious HBV vaccines.
In fact, the HBV vaccine has been so successful that it
has been adopted into 184 government immunization programs [15], which have been a driving force in its continued ability to reduce the global prevalence of HBV.
While the effect of the HBV vaccine on HBV incidence and prevalence are well-studied [2, 13, 16], far less
is known about its impact on the transmission of HDV.
In part, this lack of information is because some do not
consider HDV to be a relevant medical problem [18]. It is
this stance that once led to a decline in screening for HDV
infection [5, 10], and its subsequent rebound in parts of
Europe [18]. Even with the rebound of HDV, some public
health officials continue to only control HDV indirectly
through sustained efforts to reduce HBV, such as HBV
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vaccination, the use of harm reduction services, and education on both blood and injection safety [33], instead
of investing time and resources into developing HDV specific health interventions. Regardless of whether specific
health interventions should be developed for HDV, there
are still important questions that remain unanswered concerning HDV’s status in the world. For instance, it is
unknown what level of HBV vaccination is required so
the decline in current HDV incidence reaches the reductions called for by the Global Health Sector Strategy on
Viral Hepatitis 2016-2021 [30]. Similarly, it is also unknown whether the current HBV vaccination levels are
sufficiently high to cause the elimination of HDV, as ongoing surveillance illustrates a marked decline of HDV in
the Western world, among other regions [18].
To inform on the potential for HBV vaccination to aid
in meeting the targets of the Global Health Sector Strategy on Viral Hepatitis 2016–2021 [30], and its potential
to cause HDV elimination, we developed a mathematical model of HBV and HDV transmission. Our mathematical model considers the most common transmission
routes for both HBV and HDV infection, namely personto-person transmission, with acute and chronic stages of
infection. To calibrate our mathematical model, we used
freely available data on HBV and HDV [4, 18, 36], along
with effective HBV vaccination levels of 10.72%, 22.23%,
and 62.1% coverage, which are based on a meta-analysis
of HBV vaccination in Africa[1], along with data on the
efficacy of the HBV vaccine [8]. Using our model, we esti2022 Volume 8(1) page 61
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where βD is the transmission rate of HDV. Also considered in our model, is the birth rate (b), the proportion
of newborns with hepatitis (σ), the rate acute hepatitis infection clears or becomes chronic (γ), the proportion of acute hepatitis infections that lead to chronic disease (ρ), the recovery rate from hepatitis infection (δ),
death rate (µ), and the vaccination rate for HBV of sus2 Materials and Methods
ceptible individuals (ν). Note, parameter subscripts of B
and D correspond to the parameters associated directly
To evaluate the effect of the HBV vaccination on inhibit- with HBV infection and HDV infection, respectively. Furing the spread of HDV, we created a mathematical model ther details of parameters, including values and sources,
of HBV and HDV transmission (see Figure 1 and the Ap- are available in Table 1.
pendix). Through the mathematical model, we estimate
the effect that HBV vaccination has on HDV transmission
2.2 The reproductive numbers of HBV
by reducing the number of individuals who are susceptiand HDV
ble to HDV infection. We consider scenarios where the
effective HBV vaccination level achieves 10.72%, 22.23%, To provide insight on the potential for the HBV vaccine
and 62.1% coverage, based on the results of a recent meta- to eliminate both HBV and HDV we estimated the basic
analysis of HBV vaccination in Africa [1, 8]. Under the [9, 25], control [24], and effective [24] reproductive numscenarios, we measure the associated decline in HDV inci- bers. The reproductive numbers of HBV are estimated
dence, identify the vaccination required to reduce hepati- using the next-generation method (Appendix). Using this
tis incidence by 90%, and determine the thresholds that approach, we have that the effective reproductive number
cause hepatitis B and D elimination.
is calculated as


S
δB + µ + µB + ρB γB
B
βB + bσB .
Ref f =
2.1 Mathematical model
(γB + µ)(δB + µ + µB )
N
For our mathematical model, we consider a popula- Evaluating the effective reproductive number at the
tion divided into classes based on disease status. For disease-free equilibrium, we obtain the control reproducHBV, this amounts to individuals susceptible to infec- tive number for HBV:
tion (S), acute HBV infected individuals (AB ), chronic


δB + µ + µB + ρB γB
b
HBV infected individuals (CB ), individuals recovered
RνB =
βB
+ bσB .
(γB + µ)(δB + µ + µB )
µ+ν
from HBV infection (RB ), and HBV vaccinated individuals (V ). For HDV, due to the requirement of HBV
Further imposing that ν = 0, we obtain the basic reproinfection, we have acute HBV and HDV infected indiductive number for HBV:
viduals ([AB AD ]), chronic HBV and acute HDV infected
individuals ([CB AD ]), chronic HBV and HDV infected
R0B = RνB ν=0 .
individuals ([CB CD ]) and individuals with chronic HBV
infection that have recovered from HDV ([CB RD ]). Note, From the control reproductive number, we determine the
we do not consider a compartment where individuals have critical HBV vaccination level to cause elimination by
recovered from HBV infection and are infected with HDV, solving RνB ≤ 1 for ν.
With regards to HDV, we also use the next-generation
as HDV requires the simultaneous presence of HBV to
method to estimate the reproductive numbers (see the
complete its life cycle [14].
Our model considers the rate that susceptible individ- Appendix). Using this approach, we have that the control
reproductive number for HDV is
uals become infected with HBV to be
mate the vaccination levels required to reduce HBV and
HDV incidence by 90% (one of the primary objectives
of the Global Health Sector Strategy on Viral Hepatitis
2016–2021 [30]), and the levels required to cause both
HBV and HDV elimination.

λB =

βB 
AB + CB + [AB AD ] + [CB AD ]
N

+ [CB CD ] + [CB RD ] ,

where βB is the transmission rate of HBV and N is the
total population. In addition, the rate that HBV infected
individuals become co-infected with HDV is

βD 
λD =
[AB AD ] + [CB AD ] + [CB CD ] ,
N
www.sporajournal.org

RvD =

1
(γB + µ)(γD + µ + µB + δB )(µ + µD + δD )

·
µ2 + (µB + µD + ρB γB + γD + δB + δD )µ
+ (µB + γD + δB + ρB γB )(µD + δD )


d
+ ρB γB ρD γD βD ANB + bσD

d
+ βD (γB + µ)(ρD γD + µ + µD + δD ) CNB ,

2022 Volume 8(1) page 62
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Figure 1: Compartmental diagram of HBV and HDV co-infection. The diagram details the HBV and HDV transmission structure. Note, for ease of presentation, demographic rates are excluded.

Table 1: Parameters and sources.
Parameter
Sub-Saharan Africa population
Birth rate
Death rates
Natural
HBV
HDV
Proportion of newborns
(from infected parents) with
chronic HBV
chronic HDV
Transmission rate
HBV
HDV
Incubation period
HBV
HDV
Proportion that develops active disease
HBV
HDV
Average duration of chronic infection
HBV
HDV
Vaccination rate for HBV

www.sporajournal.org

Variable
N
b

Value
1.08 billion
0.046 year−1

Distribution

Source
[29]
[7]

µ
µB
µD

1/61.3 year−1
0.00086 year−1
0.0030 year−1

Exp(1/61.3)
Exp(0.00086)
Exp(0.0030)

[28]
Appendix
Appendix

σB
σD

0.2
0.05 · σB

U[0.0, 0.4]

[35]
[31]

βB
βD

0.288 year−1
6.79 year−1

1/γB
1/γD

91.25 days
91.25 days

ρB
ρD

0.1
0.1

1/δB
1/δD

50 years
50 years

ν

Appendix
Appendix
Tri[45, 68.75, 160]
Tri[45, 68.75, 160]

[6]
[6]
Appendix
Appendix

δ ∼Exp(1/50)
δ ∼Exp(1/50)

[34]
[34]

U[0, 0.026]

Appendix
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cB and C
cB correspond to the HBV endemic and on Viral Hepatitis 2016–2021 [30]). For the base case, we
where A
HDV free equilibrium values (Appendix). It naturally perturb the HBV endemic and HDV free equilibrium so
that 4.5% of HBV incidences are co-infected with HDV
follows that the basic reproductive number is
[21] as the initial condition, with baseline vaccination
R0D = RνD ν=0 .
rates. We then subtract the predicted incidence when
the model features a vaccination rate from the baseline
From RνD , the critical HBV vaccination level to cause the up to 0.05 per year from the base case to obtain incielimination of HDV is determined by solving RνD ≤ 1 dence averted, where the initial conditions are assumed
for ν.
the same, for each equilibrium, respectively.

2.3

HBV and HDV scenarios

To illustrate the effect of HBV vaccination on HBV and
HDV incidence, we base model demographics on the population of Sub-Saharan Africa [28]. Specifically, we use
life expectancy, birth rates, and baseline HBV vaccination
rates from the literature on Sub-Saharan Africa [1, 27, 29].
2.3.1

2.4

Sensitivity analysis

To quantify how each parameters’ uncertainty contributes
to the variability in predictions of control reproductive
numbers, we calculated variance-based first-order sensitivity indices [20, 22]. Details of the probability distributions used in the calculation of indices are available in
Table 1.

HBV vaccination

We consider effective vaccination rates of 10.72%, 22.23%,
and 62.1% to encapsulate the variety of vaccination coverages that occur in Sub-Saharan Africa [1, 8]. Specifically,
we assume the HBV vaccination rates achieve a coverage
of 13.4%, 24.7%, and 62.1% [1] with vaccine efficacies of
80%, 90%, and 100%, respectively [8]. We classify these as
high, intermediate, and low HBV endemic scenarios, respectively. For these scenarios, we obtain two estimates of
the required increase in HBV vaccination rates needed to
achieve a 90% reduction in HBV incidence. The first estimate uses the HBV endemic and HDV free equilibrium to
determine the baseline vaccination rate to reach each coverage level, and the required increase in HBV vaccination
rate to reduce HBV incidence by 90%. The second estimate follows the same procedure using the HBV and HDV
co-endemic equilibrium. We also use the HBV and HDV
co-endemic equilibrium to estimate the increase in HBV
vaccination required to reduce HDV incidence by 90%.

3

Results

By evaluating and comparing endemic equilibria at different HBV vaccination rates, we showed the upscale of vaccination required to decrease HBV incidence, and HDV
incidence by 90%, respectively. We considered three baseline scenarios of effective HBV vaccination rates based
on the literature, which achieve vaccination coverages of
10.72%, 22.23%, and 62.1% [1]. In addition to our results
based on equilibria, we also estimated HBV and HDV
incidence averted over an 8-year time horizon caused by
increasing HBV vaccination rates.

3.1

HBV endemic and HDV free scenario

In the absence of HDV, we found that the vaccination
rates required to achieve the effective vaccination coverages of 10.72%, 22.23%, and 62.1% are 0.00423 year−1 ,
0.00886 year−1 , and 0.0248 year−1 for high, intermediate, and low HBV endemic scenarios, respectively, at the
2.3.2 HBV and HDV transmission
HBV endemic and HDV free equilibrium. For the low
To calibrate HBV transmission rates, we use estimates of endemic scenario, the vaccination rate of 0.0248 year−1
the basic reproductive number for HBV [36], along with causes RνB < 1 (Figure 3), thereby rendering any comestimates of HBV recovery and mortality rates (see Ta- parison of the endemic equilibrium at higher vaccination
ble 1 and the Appendix). Similarly, to determine the rates infeasible. For the high and intermediate scenarios,
transmission rate of HDV, we use estimates of its repro- a 90% reduction in HBV incidence requires increasing the
vaccination rates to 0.0216 year−1 , and 0.0221 year−1 ,
ductive number from the literature [34] (Appendix).
from the baseline rates, respectively (Figure 2a).
2.3.3

HBV and HDV incidence averted

In addition to using the endemic equilibria to inform
on the vaccination levels required to reduce incidence by
90%, we also provide an estimate on the incidence averted
over a 8-year time horizon (the timeframe of the goals set
by health officials in the Global Health Sector Strategy
www.sporajournal.org

3.2

HBV and HDV co-endemic scenario

We found that the vaccination rates required to achieve
HBV vaccination coverages at the HBV and HDV coendemic equilibrium were similar to those of the HBV endemic and HDV free equilibrium, namely 0.00427 year−1 ,
2022 Volume 8(1) page 64
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(a)

(b)

Figure 2: Percent reduction in incidence for given vaccination rate. (a) Reduction at HBV endemic and HDV free
equilibrium (Appendix, equation 2) for high (red dashed line) and intermediate (blue dash-dot curve) transmission
at the given vaccination rate, and (b) Reduction at HBV and HDV co-endemic equilibrium (Appendix, equation 3)
for high (red dashed curve), and intermediate (blue dash-dot curve) transmission at the given vaccination rate.
to 0.0216 per year averts 13167 (95% CI 13018, 13317)
incidence of HBV over 8 years, and 61.6 (95% CI 60.2,
62.9) incidence of HDV (Figure 4). In addition, when we
consider increasing the vaccination rate for our intermediate HBV endemic scenario from 0.00886 to 0.0221 per
year, a total of 9870 (95% CI 9758, 9982) incidence of
HBV, and 46.2 (95% CI 45.2, 47.2) incidence of HDV are
averted (Figure 4). Finally, for our low HBV endemic scenario, increasing the vaccination rate from 0.0248 to 0.05
per year averted 16375 (95% CI 16194, 16555) incidence
of HBV, and 77.7 (95% CI 76.1, 79.4) incidences of HDV
(Figure 4).

Figure 3: Control reproductive number for HBV and
HDV versus the annual vaccination rate. The critical
value for disease elimination (red dash-dot line), RνB 3.4 Sensitivity analysis
(black solid curve) and RνD (blue dashed curve).
The variance-based sensitivity analysis of model parameters shows that RνB and RνD were most sensitive to life
expectancy (i.e., the natural death rate) and the duration
0.00892 year−1 , and 0.0248 year−1 , respectively. Howof chronic infection with HBV (Figure 5). Beyond these
ever, achieving a 90% reduction in HBV incidence reparameters, RνB was also sensitive to the HBV vaccinaquired higher HBV vaccination rates of 0.0281 year−1 ,
tion rate, although this had little effect on RνD (Figure 5).
and 0.0315 year−1 (Figure 2b), respectively. When conIn a similar fashion, RνD was sensitive to the duration of
sidering HDV, achieving a 90% reduction for the high
chronic infection with HDV, but this parameter had a
endemic setting required an increase in the HBV vaccinanegligible impact on RνB (Figure 5). Other model paramtion rate to 0.00643 year−1 . For the intermediate HBV
eters had a minimal impact on any variability of both RνB
endemic scenario, the increase in vaccination required to
and RνD (Figure 5).
reduce HDV incidence by 90% was negligible, as RνD = 1.
Finally, for the low endemic scenario, the HBV vaccination rate causes RνD < 1 (Figure 3), therefore the HDV- 4
Discussion
related states are infeasible for determining the reduction.
The analysis of our mathematical model of HBV and
HDV co-infection predicts that HBV vaccination levels
3.3 HBV and HDV incidence averted
beyond 0.0221 year−1 are required to reduce both HBV
For our high HBV endemic scenario, our model predicts and HDV incidence by 90%. Furthermore, if this vacciincreasing HBV vaccination rates from 0.00427 per year nation level is reached, our results on the control reprowww.sporajournal.org
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(a)

(b)

Figure 4: HBV and HDV incidence averted. (a) HBV incidence averted and (b) HDV incidence averted were
calculated by subtracting the total incidence over an 8-year time horizon, for the given vaccination rate, from baseline
incidence predictions of HBV and HDV, respectively, in high (red dashed curve), intermediate (blue dash-dot solid
curve), and low (black solid curve) HBV endemicity.
ductive numbers for both diseases show that their elimination would be well within the realm of possibilities, as
an annual vaccination rate of 0.025 causes RνB < 1.
The findings of our work reaffirm theoretical studies
that show HDV has an impact on the spread and control
of HBV [34]. Specifically, our results indicate that the
presence of HDV requires a higher HBV vaccination rate
to cause the elimination of both diseases. A potential
workaround of this issue is to first focus on HDV elimination, given the relatively low HBV vaccination rate
required to accomplish this feat, and then focus on HBV
elimination. While such an endeavor would likely take a
longer period to complete, it would entail less upscaling
of HBV vaccination and therefore may be more feasible
in regions where health resources are scarce.
As our work considers HBV and HDV transmission
among a general population, an important direction for
future work is to include demographic structure to reflect
the role that at-risk communities, such as drug injectors
and sex workers, play in enabling the persistence of both
HBV and HDV. Similarly, modifications to our model to
reflect individuals’ knowledge of HBV and HDV infection
status and stratification by age would also likely prove to
be fruitful avenues for further investigation.
To obtain our results, we made several simplifying assumptions. To begin, our model only accounts for stages
of acute and chronic infection for both HBV and HDV.
Therefore, our model does not reflect other disease stages,
such as superinfection, latent infection, or the difference
between chronically infected individuals that receive or
do not receive drug treatment, such as entecavir for HBV
[32], or in-development drug treatments for HDV [12]. In
addition, we did not account for the difference in transmission potential between acute and chronically infected
www.sporajournal.org

individuals, which has been shown to affect critical vaccination thresholds [19], nor do we account for the impact of
co-infection with other types of viral hepatitis that commonly occur, such as hepatitis C [3]. In addition, our
model is calibrated to describe HBV and HDV transmission in Sub-Saharan Africa, although with modest modifications it could be used to evaluate the HBV and HDV
interventions under different demographic settings.

5

Conclusion

In summary, our results indicate that HDV elimination is
likely underway in the vast majority of low HBV transmission settings. Our results also suggest that modest
increases in HBV vaccination rates in intermediate and
high HBV endemic settings could lead to the elimination
of HBV and HDV. As such, these findings reinforce the
idea that the elimination of HBV and HDV are feasible
endeavors. Thus, with sufficient investments to scale up
global hepatitis prevention, testing, and treatment services, both HBV and HDV could be eliminated in time
for the WHO’s 2030 target date.

Author Contributions
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participated in the drafting and editing of the manuscript.
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(a)

(b)

Figure 5: Variance-based sensitivity indices. (a) control reproductive number for HBV and (b) control reproductive
number for HDV. Index calculations are based on 10,000 random parameter samples.

6

dAB
= bσB (AB + CB ) + λB S − γB AB
dt
− µAB − λD AB ,
dCB
= ρB γB AB − (µ + µB + δB )CB − λD CB ,
dt
dRB
= (1 − ρB )γB AB + (1 − ρB )γB [AB AD ]
dt

+ δB CB + [CB RD ] + [CB AD ]

Appendix

This appendix provides further details on the hepatitis
B and D co-infection model. We outline the differential
equations used in model simulations, and the methods
for estimating the reproductive numbers [9, 24] of both
hepatitis B and D.

− µRB + δD [CB CD ],

6.1
6.1.1

Model equations
Hepatitis B and D system

d[CB AD ]
= ρB γB [AB AD ] − γD [CB AD ]
dt
− (µ + µB + δB )[CB AD ] + λD CB ,

d[CB CD ]
For our mathematical model, we consider a population
= ρD γD [CB AD ] − (µ + µD + δD )[CB CD ],
dt
that divides the population-based on susceptibility to ind[CB RD ]
fection, acute infection, chronic infection and immunity
= (1 − ρD )γD [CB AD ]
from infection. For hepatitis B, this amounts to suscepdt
tible individuals (S), acute hepatitis B infected individ− (µ + µB + δB )[CB RD ],
uals (AB ), chronic hepatitis B infected individuals (CB ),
dV
= νS − µV,
(1)
the recovered individuals from hepatitis B (RB ), and the
dt
hepatitis B vaccinated individuals (V ). The population
where the force of infection for hepatitis B is given by,
infected with hepatitis B is further subdivided based on
hepatitis D infection status, namely acute hepatitis B
βB 
λ
=
AB + CB + [AB AD ] + [CB AD ]
B
and D infected individuals ([AB AD ]), chronic hepatitis
N

B and acute hepatitis D infected individuals ([CB AD ]),
+ [CB CD ] + [CB RD ] ,
chronic hepatitis B and D infected individuals ([CB CD ]),
and chronic hepatitis B infected individuals that have re- and the force of infection for hepatitis D is given by,
covered from hepatitis D ([CB RD ]). To describe the tran
βD 
λD =
[AB AD ] + [CB AD ] + [CB CD ] .
sition between compartments for hepatitis B and D, we
N
consider the system of differential equations,
dS
= bN − bσB (AB + CB ) − λB S
dt

− bσD [AB AD ] + [CB AD ] + [CB CD ]
− (ν + µ)S,
www.sporajournal.org

6.2
6.2.1

Model equilibria
Hepatitis B and D equilibria

The model (1) has 3 valid equilibria: a disease-free equilibrium, a hepatitis B endemic and hepatitis D free equi2022 Volume 8(1) page 67
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ρB γB
fB ,
A
µ + µB + δB + λD


1
^
g
f
R
B = µ (1 − ρB )γB AB + [AB AD ]

librium, and a hepatitis B and D co-endemic equilibrium.
The disease-free equilibrium is
S DF E =

b
N,
µ+ν

V DF E =

fB =
C

ν b
N,
µµ+ν


^
fB + [C^
+ δB C
B AD ] + [CB RD ]

+ δD [C^
B CD ] ,

and
E
DF E
DF E
E
ADF
= CB
= RB
= [AB AD ]DF
B
B
E
E
E
= [CB AD ]DF
= [CB CD ]DF
= [CB RD ]DF
= 0.
B
B
B

When hepatitis B is endemic and hepatitis D free, the
equilibrium is
Sb =

N
βB (µ + µB + δB + ρB σB )

· µ2 + (µB + δB + γB − bσB )µ

cB =
A

[C^
B AD ] =
[C^
B CD ] =


+ (µB + δB − bρB σB )γ − bσB (µB + δB ) ,

[C^
B RD ] =
Ve =

N
βB (γB + µ)(µ + µB + δB + ρB σB )

· −µ3 − (µB + ν + bσB + γB + δB )µ2


+ (ν + µB + δB + ρB γB )σB + βB b

ψ1 µ + ψ0
,
ϕ3 + ϕ2 µ2 + ϕ1 µ + ϕ0
f
ρB γB [A^
B AD ] + λD CB
,
µ + µB + δB + γD
ρD γD [C^
B AD ]
,
µ + µB + δD
(1 − ρD )γD [C^
B AD ]
,
µ + µB + δD
ν e
S,

[A^
B AD ] = λD

µ3

µ

(3)

where
ϕ3 = 1,
ϕ2 = µD + δB − bσD + δD + γD + µB γB ,
ϕ1 = −(δD + γD + ρB γB + µD + µB + δB )bσD
+ (µB + γB + δB + γD )µD



− (ν + µB + δB )γB − ν(µB + δB ) µ

+ (µB + γB + δB + γD )δD

+ (µB + δB + ρB γB )(νσB + βB )b

− γB ν(µB + δB ) ,

+ γB (δB + γD + µB ),


ϕ0 = −(δB + γD + ρB γB + µB )µD

ρB γB
,
µ + µB + δB
(1 − ρB )(µ + µB ) + δB c
d
CB ,
R
B =
ρB µ
νb
Vb = S,
µ

− (δB + γD + ρB γB + µB )δD

− ρD ρB γD γB bσD

cB =
C

+ γB (µD + δD )(δB + γD + µB ),
fB + (γD + δB + δD + µB + µD )A
fB ,
ψ1 = bσD C
fB
ψ0 = (µD + δD )(δB + γD + µB )A

and
\
\
\
[A\
B AD ] = [CB AD ] = [CB CD ] = [CB RD ] = 0.

fB (ρD γD + δD + µD )σD .
+ bC

(2)

Finally, when both hepatitis B and hepatitis D are endemic, we have the co-endemic equilibrium, which is defined implicitly for the ease of presentation, is

1
fB + C
fB )
Se =
bN + bσB (A
λB + ν + µ

^
^
+ bσD [A^
,
B AD ] + [CB AD ] + [CB CD ]

6.3
6.3.1

The reproductive numbers
The reproductive numbers for hepatitis B

+ µ2 + (µB + δB + γB − bσB )µ

To compute the basic reproductive number for hepatitis B we apply the standard next-generation approach.
The system (1) has two stages that contribute to hepatitis B: AB and CB . By, decoupling the system into new
hepatitis B infections and transitions between hepatitis B
infection classes, it follows that


DF E
DF E
βB S N + bσB βB S N + bσB
,
FB =
0
0

+ γB (µB + δB )

and

fB = λB (µ + µB + δB + λD )
A

· λ2D + (2µ + µB + δB + γB − bσB )λD

− b(µB + δB + ρB γB )σB
www.sporajournal.org

−1

e
S,


VB =

γB + µ
−ρB γB


0
.
δB + µ + µB
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Thus, the next-generation matrix is GB = FB VB−1 , which
equates to
(βB S DF E +bσB N )(µ+µB +δB +ρB γB )
N (γB +µ)(δB + mu+µB )

βB S DF E +bσB N
N (δB +µ+µB )

0

0

!
.

Using FD and VD , we take the spectral radius of FD VD−1
to estimate the control reproductive of hepatitis D as
RνD =

From computing the spectral radius of GB , we obtain the
basic reproductive number to be

R0B =

R0D = RνD

b
µN

in the absence of vaccination. From
where S F E =
the calculation of R0B , it follows that the effective reproductive number is
B
Ref
f =

βB (µ + µB + δB + ρB γB ) S
(γB + µ)(δB + mu + µB ) N
bσB (µ + µB + δB + ρB γB )
,
+
(γB + µ)(δB + mu + µB )

and the control reproductive number is

6.3.2

+ (µB + γD + δB + ρB γB )(µD + δD )


g
+ ρB γB ρD γD βD ANB + bσD

g
C
B
+ βD (γB + µ)(ρD γD + µ + µD + δD ) N .

βB (µ + µB + δB + ρB γB ) S DF E
(γB + µ)(δB + mu + µB ) N
bσB (µ + µB + δB + ρB γB )
+
, (4) Finally, the basic reproductive number is obtained by
(γB + µ)(δB + mu + µB )
D

RνB =

1
(γB + µ)(γD + µ + µB + δB )(µ + µD + δD )

·
µ2 + (µB + µD + ρB γB + γD + δB + δD )µ

βB (µ + µB + δB + ρB γB ) b
(γB + µ)(δB + mu + µB ) µ + ν
bσB (µ + µB + δB + ρB γB )
.
+
(γB + µ)(δB + mu + µB )

The reproductive numbers for hepatitis D

6.4

ν=0

.

(5)

Hepatitis transmission rates

To estimate the transmission rate of hepatitis B we use
estimates on the prevalence of hepatitis B, the proportion
of chronic hepatitis B, the basic reproductive number of
hepatitis B [36] along with the endemic equilibrium for
hepatitis B (4). It follows for R0B = 2.406 [36] that
βB ≈ 0.288 year−1 .
Chronic infection with hepatitis B reduces the average life
span of 61.3 years by approximately 4.8 years [26]. Thus,
on average, we have that
1
≈ 56.5 years.
µ + µB
It follows that µB ≈ 0.00139 year−1 . Similarly, chronic
hepatitis D co-infection typically leads to death 10 years
sooner than mono-infection with hepatitis [14]. Thus, we
have that
1
≈ 46.5 years,
µ + µD

To compute the basic reproductive number for hepatitis D we once again apply the standard next-generation
approach. The system (1) has three stages that conand so
tribute to hepatitis D: [AB AD ], [CB AD ], and [CB CD ].
µD ≈ 0.00519 year−1 .
By decoupling the system into new hepatitis D infections
and transitions between hepatitis D infection classes, it To estimate the transmission rate of hepatitis D, the literature place RνD ≈ 1.01 when ν = 0.00025 year−1 , with
follows that
an R0D ≈ 1.09 under an average lifespan of 55.6 years


g
g
g
[34]. When considering a lifespan of µ1 = 56.5 years, and
βD ANB + bσD ANB + bσD ANB + bσD


g
g
g
the birth rate b=0.046 year−1 , we have that RνD ≈ 1.25
B
FD =  βD C
βD CNB
βD CNB  ,
N
when ν = 0.00025 year−1 . Given this estimate, and the
0
0
0
parameter values from Table 1, it follows from (5) that
and

βD ≈ 6.79 year−1 ,


VD

γB + µ
= −ρB γB
0

0
γD + δB + µ + µB
−ρD γD

www.sporajournal.org


0
.
0
δD + µ + µD

and in the absense of vaccination that
R0D ≈ 1.40.
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The proportion that develops
active disease

To estimate the proportion of individuals that develop
active disease we use current estimates that 90% of perinatal infections are active, 30% of childhood infections
(¡6 years) are active, and 10% of other infections are active [26]. Thus, given that approximately 0.142% of individuals are classified as perinatal, 2.9% are classified as
children under 6 years [17], it follows that
ρ = 0.9(0.00142) + 0.29(0.028) + 0.1(0.96) ≈ 0.10.

6.5

Effective vaccination rate estimation

To estimate the effective vaccination rate of hepatitis B
we make use of the HBV endemic and HDV free equilibrium, in addition to the HBV and HDV co-endemic
equilibrium. Specifically, we solve
V S + V + AB + CB + RB + [AB AD ]
−1
+ [CB AD ] + [CB CD ] + [CB RD ]

= 0,
eqb

The increasing prevalence of hepatitis delta virus
(HDV) infection in South London. Journal Of Medical Virology, 80, 277–282.
[6] Goyal, A., & Murray, J. (2016). Recognizing the impact of endemic hepatitis D virus on hepatitis B virus
eradication. Theoretical Population Biology, 112, 60–
69.
[7] Greenhalgh, S., Ndeffo, M., Galvani, A., & Parikh, S.
(2015). The epidemiological impact of HIV antiretroviral therapy on malaria in children. AIDS (London,
England), 29, 473–482. http://www.ncbi.nlm.nih.
gov/pubmed/25486414
[8] Hamborsky, J., Kroger, A., & Wolfe, S. (2015). Epidemiology and prevention of vaccine-preventable diseases. Centers for Disease Control and Prevention.
[9] Heffernan, J., Smith, R., & Wahl, L. (2005). Perspectives on the basic reproductive ratio. Journal
Of The Royal Society, Interface, 2, 281–293. http:
//www.ncbi.nlm.nih.gov/pubmed/16849186%20

where eqb represents either the HBV endemic and HDV [10] Holmberg, S., & Ward, J (2010). Hepatitis Delta:
Seek and Ye Shall Find. The Journal Of Infectious
free equilibrium, or the HBV and HDV co-endemic equiDiseases, 202, 822–824.
librium, depending on scenario, and θ is 10.72%, 22.23%,
or 62.1%, depending on the high, intermediate, or low
[11] Jefferies, M., Rauff, B., Rashid, H., Lam, T., &
HBV endemicity, respectively.
Rafiq, S. (2018). Update on global epidemiology of
viral hepatitis and preventive strategies. World Journal Of Clinical Cases, 6, 589–599.
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